BioAtla Presents Phase 2 Ozuriftamab Vedotin…

If there’s anxiety lingering after the FDA’s summer ruling about potential cancer toxicity with peroxisome proliferator-activated receptors (PPARs), you wouldn’t know it from Wyeth – which entered a potential $372 mil- lion deal with Plexxikon Inc. to develop treatments for diabetes and metabolic disorders.